Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome. An update

Hematology/Oncology Clinics of North America

Volumn 27, Issue 3, 2013, Pages 565-584

  Tsai, Han Mou ^a  

^a IMAH Hematology   (United States)

Author keywords

ADAMTS13; Atypical hemolytic uremic syndrome; Complement regulators; Microangiopathic hemolysis; Shear stress; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; PREDNISONE; RITUXIMAB; THROMBOMODULIN; TICLOPIDINE; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ALLERGIC REACTION; BLOOD TRANSFUSION; COMORBIDITY; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MICROCIRCULATION; MORTALITY; MUTATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SHEAR STRESS; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ADAM PROTEINS; ADULT; ANIMALS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84878255217     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.02.006     Document Type: Review

References (32)

1. Tsai H.M. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007, 21:609-632. v.
2. George J.N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010, 116:4060-4069.
3. Tsai H.M. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012, 38:469-482.
4. Reti M., Farkas P., Csuka D., et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012, 10:791-798.
5. Sanchez-Luceros A., Farias C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004, 92:1320-1326.
6. Cao W.J., Niiya M., Zheng X.W., et al. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008, 6:1233-1235.
7. Motto D.G., Chauhan A.K., Zhu G., et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005, 115:2752-2761.
8. Banno F., Kokame K., Okuda T., et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006, 107:3161-3166.
9. Schiviz A., Wuersch K., Piskernik C., et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012, 119:6128-6135.
10. Feys H.B., Roodt J., Vandeputte N., et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010, 116:2005-2010.
11. Ermini L., Goodship T.H., Strain L., et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 2012, 49:640-648.
12. Heurich M., Martinez-Barricarte R., Francis N.J., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011, 108:8761-8766.
13. Dragon-Durey M.A., Sethi S.K., Bagga A., et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010, 21:2180-2187.
14. Noris M., Caprioli J., Bresin E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
15. Fakhouri F., Roumenina L., Provot F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010, 21:859-867.
16. Tsai H.M., Rice L., Sarode R., et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000, 132:794-799.
17. Hirata S., Okamoto H., Ohta S., et al. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease. Rheumatology (Oxford) 2006, 45:1046-1047.
18. Torok N., Niazi M., Al A.Y., et al. Thrombotic thrombocytopenic purpura associated with anti-glomerular basement membrane disease. Nephrol Dial Transplant 2010, 25:3446-3449.
19. Salmon J.E., Heuser C., Triebwasser M., et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011, 8:e1001013.
20. Tsai H.M. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009, (112):S11-S14.
21. Manea M., Kristoffersson A., Schneppenheim R., et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007, 138:651-662.
22. Gutterman L.A., Kloster B., Tsai H.M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002, 28:385-391.
23. Elliott M.A., Heit J.A., Pruthi R.K., et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009, 83(4):365-372.
24. Scully M., McDonald V., Cavenagh J., et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011, 118:1746-1753.
25. Hart D., Sayer R., Miller R., et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura-favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol 2011, 153:515-519.
26. Cataland S.R., Jin M., Lin S., et al. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008, 83:911-915.
27. Loirat C., Babu S., Furman R., et al. Eculizumab efficacy and safety inpatients with atypical hemolyticuremic syndrome (aHUS) resistanttoplasmaexchange/infusion. Haematologica 2011, 96:S2-S979.
28. Loirat C., Muus P., Legendre C., et al. A phase II study of eculizumab in patients with atypical hemolyticuremic syndrome receiving chronic plasma exchange/infusion. Haematologica 2011, 96:S2-S980.
29. Kelly R.J., Hill A., Arnold L.M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011, 117:6786-6792.
30. Saland J.M., Ruggenenti P., Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20:940-949.
31. Weitz M., Amon O., Bassler D., et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:1325-1329.
32. Nester C., Stewart Z., Myers D., et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011, 6:1488-1494.